Taylor Frigon Capital Management LLC Has $1.67 Million Stock Holdings in Compugen Ltd. (NASDAQ:CGEN)

Taylor Frigon Capital Management LLC cut its stake in Compugen Ltd. (NASDAQ:CGEN) by 9.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,093,046 shares of the biotechnology company’s stock after selling 108,477 shares during the period. Taylor Frigon Capital Management LLC owned approximately 1.22% of Compugen worth $1,672,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. raised its holdings in Compugen by 75.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 8,350 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Compugen by 82.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock valued at $497,000 after purchasing an additional 124,190 shares during the last quarter. Finally, Atom Investors LP increased its stake in shares of Compugen by 27.5% in the 3rd quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 32,701 shares during the last quarter. 12.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer initiated coverage on Compugen in a research note on Monday, January 13th. They issued an “outperform” rating and a $4.00 price target on the stock.

Compugen Stock Performance

Shares of CGEN opened at $1.95 on Thursday. Compugen Ltd. has a 52-week low of $1.35 and a 52-week high of $3.03. The business’s fifty day moving average is $2.02 and its 200-day moving average is $1.83. The firm has a market cap of $174.01 million, a price-to-earnings ratio of 97.50 and a beta of 2.65.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.